Robeco Institutional Asset Management B.V. Buys 43,926 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Robeco Institutional Asset Management B.V. lifted its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 8.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 548,761 shares of the biopharmaceutical company’s stock after buying an additional 43,926 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Royalty Pharma were worth $13,999,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. lifted its stake in shares of Royalty Pharma by 5.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock worth $40,705,000 after purchasing an additional 70,130 shares during the period. Van ECK Associates Corp lifted its stake in shares of Royalty Pharma by 171.1% in the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock worth $2,777,000 after purchasing an additional 64,057 shares during the period. Summit Global Investments bought a new position in shares of Royalty Pharma in the 3rd quarter worth approximately $735,000. Pallas Capital Advisors LLC bought a new position in shares of Royalty Pharma in the 4th quarter worth approximately $2,355,000. Finally, Two Sigma Advisers LP lifted its stake in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.0 %

Shares of RPRX opened at $31.58 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $32.21. The company has a 50 day simple moving average of $27.23 and a two-hundred day simple moving average of $27.50. The firm has a market cap of $18.61 billion, a P/E ratio of 16.36 and a beta of 0.47.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RPRX. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Finally, TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.